OneRNA offers a platform that analyzes the full transcriptome—over 20,000 mRNAs—in patient tissue samples to identify approved drugs for repurposing and to design novel RNA therapeutics.
Funding
$4.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer molecular profiling relies on DNA panels that assess limited gene sets, often identifying actionable drugs for only a minority of patients. This narrow view misses the broader transcriptomic landscape, limiting personalized treatment options and clinical trial matching.
Solution
OneRNA’s platform performs comprehensive RNA sequencing of patient tissue, analyzing the full transcriptome of over 20,000 mRNAs. By applying AI-driven analytics to the expression data, the system identifies existing approved drugs that can be repurposed for the individual’s tumor profile and designs novel RNA‑based therapeutics. The approach is tissue‑ and disease‑agnostic, enabling rapid generation of multiple treatment recommendations—including clinical trial options—for virtually every cancer patient. Validation in breast and ovarian cancer demonstrates its ability to expand therapeutic choices beyond what DNA panels provide.
Target Audience
Primary customers are oncology clinics, pathology laboratories, and pharmaceutical companies seeking to expand precision‑medicine options for cancer patients.
Features
- Whole‑transcriptome sequencing covering >20,000 mRNA targets per sample
- AI algorithms that match expression signatures to approved drug repurposing opportunities
- Computational design of bespoke RNA therapeutics tailored to the patient’s molecular profile
- Automated generation of personalized treatment reports with drug and clinical trial suggestions
- Scalable, tissue‑agnostic workflow that can be integrated into standard pathology labs